Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors

Cell Host Microbe. 2021 Oct 13;29(10):1573-1588.e7. doi: 10.1016/j.chom.2021.08.001. Epub 2021 Aug 27.

Abstract

Despite overall success, T cell checkpoint inhibitors for cancer treatment are still only efficient in a minority of patients. Recently, intestinal microbiota was found to critically modulate anti-cancer immunity and therapy response. Here, we identify Clostridiales members of the gut microbiota associated with a lower tumor burden in mouse models of colorectal cancer (CRC). Interestingly, these commensal species are also significantly reduced in CRC patients compared with healthy controls. Oral application of a mix of four Clostridiales strains (CC4) in mice prevented and even successfully treated CRC as stand-alone therapy. This effect depended on intratumoral infiltration and activation of CD8+ T cells. Single application of Roseburia intestinalis or Anaerostipes caccae was even more effective than CC4. In a direct comparison, the CC4 mix supplementation outperformed anti-PD-1 therapy in mouse models of CRC and melanoma. Our findings provide a strong preclinical foundation for exploring gut bacteria as novel stand-alone therapy against solid tumors.

Keywords: Clostridiales; cancer; colorectal cancer; gut microbiota; immunotherapy; solid tumors; tumor models; tumor therapy.

MeSH terms

  • Animals
  • Biological Therapy*
  • CD8-Positive T-Lymphocytes / immunology
  • Clostridiales / immunology*
  • Clostridiales / physiology
  • Colorectal Neoplasms / immunology*
  • Colorectal Neoplasms / microbiology
  • Colorectal Neoplasms / therapy*
  • Gastrointestinal Microbiome*
  • Humans
  • Immunity
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Symbiosis